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Introduction
Cardiovascular diseases are a major cause of morbidity and mor-
tality in patients with diabetes.
1) Conventional risk factors such as 
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hypertension, dyslipidemia, and smoking are important in the de-
velopment of diabetic cardiovascular complications, but they can 
explain only part of excess risk. Recent studies have suggested that 
hyperglycemia is also related to increased cardiovascular risk.
2-4) One 
of the potential mechanisms through which hyperglycemia may 
contribute to cardiovascular disease is through the formation of 
advanced glycation end-products (AGEs).
Advanced glycation end-products are bioactive molecules form-
ed by non-enzymatic glycation of proteins, lipids and nucleic acid. 
AGEs increase in concentration with age and the generation of AGEs 
is accelerated by sustained hyperglycemia.
5) AGEs are related to in-
creased arterial stiffness, which is an independent contributing fac-
tor for coronary artery disease (CAD), by inducing collagen cross-link-
ing in the vessel wall.
6) Increased arterial stiffness and decreased 
vascular distensibility lead to increased systolic pressure and cardiac 
afterload, and decreased diastolic blood pressure, which potentially 336  Advanced Glycation End-Products and Coronary Artery Disease
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compromises coronary blood flow.
7)8) AGEs also contribute to the 
development of atherosclerosis by binding to specific receptors, such 
as receptor for AGEs (RAGE), on endothelial cells.
Serum levels of AGEs are increased in both diabetic
9)10) and non-
diabetic
11) patients with CAD. Recently, elevated serum levels of AGEs 
have been reported to be associated with increased aortic stiffness 
in adults.
12) We postulated that serum levels of AGEs are useful for 
predicting the presence or severity of CAD, and elevated serum lev-
els of AGEs are associated with increased aortic stiffness in patients 
suspected of having CAD. To address this hypothesis, we investigat-
ed whether serum levels of AGEs were different with and without 
CAD, and correlated serum levels of AGEs with brachial-ankle pulse 
wave velocity (baPWV), as a marker of arterial stiffness, according 
to the status of diabetes in patients with suspected of having CAD.
Subjects and Methods
Study population
We studied 145 consecutive patients, who had been referred to 
a tertiary referral hospital to be evaluated for suspected CAD. All sub-
jects underwent an invasive coronary angiogram to verify the pres-
ence of obstructive CAD, and serum levels of AGEs and baPWV were 
also measured.
Advanced glycation end-products
Serum levels of AGEs were measured with a non-competitive en-
zyme-linked immunosorbent assay. A 96-well microplate was coat-
ed at 4°C overnight with serially diluted AGE-bovine serum albumin 
(BSA) as the standard, or diluted serum samples. Unbound sites were 
blocked with 2% skim milk, 0.5% BSA, and 0.5% gelatin in 0.05 M 
carbonate buffer for 1 hour and washed with phosphate buffered 
saline (0.05% Tween-20). Each well was incubated for 2 hours with 
anti-AGE monoclonal antibody (dilution 1 : 1000; Transgenic, Kuma-
moto, Japan). The plate was washed again and incubated with hor-
seradish peroxidase-labeled goat anti-mouse IgG antibody (dilution 
1 : 2000; Zymed, San Francisco, CA, USA) for 1 hour. The unbound 
antibodies were removed by washing and bound antibodies were 
detected by incubation with 3,3’,5,5’-tetramethylbenzidine sub-
strate for 30 minutes. After the reaction was stopped by 1 M sulfuric 
acid, the resultant color reaction was read at 450 nm using a Victor2 
apparatus (Perkin Elmer Life Sciences, Turku, Finland).
13)
Coronary angiography
Coronary angiography was performed through the right radial ar-
tery, or, if this approach was considered difficult, through the right 
femoral artery. Obstructive CAD was defined as a reduction of 50% 
or more in the luminal diameter of at least one major epicardial cor-
onary artery, as determined by quantitative coronary angiography 
analysis. The severity of CAD was determined by the number of 
diseased vessels with obstructive CAD and identified by the modi-
fied Gensini scoring system, which is used to reflect the extent of 
coronary atherosclerosis by calculating the score based on the num-
ber of stenotic coronary artery segments, the degree of their lumen 
stenosis, and the localization of stenotic changes.
14)
Brachial-ankle pulse wave velocity
All subjects abstained from caffeine-containing food or drink for 
at least 45 minutes prior to measurement of baPWV. After a subject 
had been resting in the supine position for at least 5 minutes in a 
quiet room, blood pressure and baPWV were measured using a VP-
1000 automated waveform analyzer (Colin Medical Instruments, 
Komaki, Japan). Blood pressure was measured in both arms with the 
blood pressure cuffs of the device, and the higher value was used 
for the analysis. The highest value of baPWV measured on either 
side of each patient was used for the analysis.
Statistical analyses
Values are expressed as mean±SD. Comparison of the continuous 
variables between subgroups was conducted via unpaired t-test 
and one-way analysis of variance test, and categorical variables be-
tween subgroups was conducted via chi-square test. Correlations 
were assessed using Pearson’s correlation test. Receiver operating 
characteristic (ROC) curve analysis was used to determine the op-
timal cutoff point of the serum levels of AGEs for predicting ob-
structive CAD. Multiple regression analysis using serum levels of 
AGEs, creatinine, and age as independent variables significantly 
different in univariate analysis were performed for the presence of 
obstructive CAD and the associations with the number of vessel 
diseases (VDs). All analyses were conducted using the Statistical 
Package for the Social Sciences (SPSS) statistical package ver. 15 
(SPSS Inc., Chicago, IL, USA) and p<0.05 was considered to be sig-
nificant.
Results
Baseline characteristics
The clinical characteristics of the patients in this study are shown 
in Table 1. This study included 44 diabetics (65±9 years, 59% male) 
and 101 non-diabetics (63±9 years, 57% male). Both diabetic and 
non-diabetic individuals were classified into three subgroups based 
on the number of diseased vessels with obstructive CAD: 0, 1, and 
more than 2 VDs and calculated using the modified Gensini scor-
ing system. Among these subgroups, there were significant differ-
ences in age, serum levels of creatinine, and AGEs in diabetic pa-337 Ki-Bum Won, et al.
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tients and, for sex, incidence of hypertension and smoking, serum 
levels of creatinine in non-diabetic patients. Modified Gensini 
score differed significantly among subgroups classified by the 
number of VDs in both diabetics and non-diabetics.
Serum advanced glycation end-products and obstructive 
coronary artery disease
Serum levels of AGEs were significantly higher in diabetics with 
obstructive CAD than in those without obstructive CAD (2.16±0.29 
vs. 1.85±0.29 mU/mL, p=0.010) (Fig. 1), but did not differ significant-
ly between non-diabetics with and without obstructive CAD (1.86± 
0.39 vs. 1.90±0.34 mU/mL, respectively; p=0.590). In the ROC analy-
sis to determine the optimal cut-off value of serum levels of AGEs 
as a predictor of obstructive CAD in diabetics, the cut-off value of 
1.98 mU/mL had 64% sensitivity and 63% specificity in predicting 
obstructive CAD (p=0.031) (Fig. 2). 
Serum levels of AGEs were significantly correlated with the num-
ber of VDs in diabetics (r=0.504, p<0.001) (Fig. 3), but they were not 
significantly correlated with the number of VDs in non-diabetic 
patients (r=-0.136, p=0.174). 
Multiple regression analysis suggested that serum levels of AGEs 
and creatinine could independently predict obstructive CAD, and that 
serum levels of AGEs were associated with the number of VDs in 
diabetics (Table 2).
Table 1. Clinical characteristics of the study subjects
Non-diabetes patients (n=101)
p
Diabetic patients (n=44)
p
Number of obstructive coronary arteries Number of obstructive coronary arteries
0 (n=49)
Obstructive CAD
0 (n=8)
Obstructive CAD
Total 
(n=52)
1 
(n=23)
≥2 
(n=29)
Total 
(n=36)
1 
(n=9)
≥2 
(n=27)
Men (%) 23 (22.8) 35 (35) 11 (11) 24 (24) 0.005 3 (6.8) 23 (52) 6 (14) 17 (39) 0.382
Age (years) 61±9 64±8 62±9 65±8 0.129 59±8 66±9 60±6 68±9
‡ 0.016
SBP (mm Hg)  135±20 139±28 136±35 141±21 0.611 128±21 142±29 154±42 138±23 0.254
DBP (mm Hg) 77±13 79±12 79±14 80±11 0.676 80±17 71±14 80±14 68±13 0.110
Heart rate (bpm) 61±14 62±14 66±18 59±9 0.215 69±18 65±11 66±15 65±11 0.677
Hypertension (%) 20 (20) 33 (33)
‡ 18 (18) 15 (15) 0.012 5 (11) 26 (59) 7 (16) 19 (43) 0.789
Duration of DM (years) - - - - - 4.5±6.2 6.8±6.9 5.5±4.7 7.2±7.6 0.644
Smoker (%) 13 (15) 30 (35)* 10 (12) 20 (23) <0.001 2 (5) 17 (46) 5 (14) 12 (32) 0.379
Serum creatinine (mg/dL) 0.86±0.24 0.94±0.25 0.83±0.25 1.03±0.21 0.003 0.68±0.20 0.89±0.19* 0.87±0.25 0.89±0.16
‡ 0.024
Total cholesterol (mg/dL) 171±34 182±37 185±37 179±37 0.272 177±40 165±45 147±35 171±47 0.299
Triglycerides (mg/dL) 119±56 133±54 122±38 141±63 0.251 118±36 158±105 219±173 137±60 0.053
HDL-C (mg/dL) 52±12 48±11 48±12 49±11 0.336 49±6 49±12 41±8 51±12 0.075
LDL-C (mg/dL) 97±31 106±28 113±26 103±30 0.649 118±27 100±35 81±44 108±31 0.397
FBS (mg/dL) 97±11 99±13 99±13 99±12 0.805 142±25 125±31 140±46 121±26 0.167
HbA1c (%) 5.7±0.4 5.8±0.4 5.7±0.3 5.8±0.5 0.666 7.2±0.9 7.1±1.1 7.3±1.9 7.0±0.7 0.751
AGEs (mU/mL) 1.90±0.34 1.86±0.39 1.98±0.45 1.76±0.32 0.096 1.85±0.29 2.16±0.29* 1.96±0.18 2.23±0.29*
† 0.002
BaPWV (cm/s) 1622±464 1612±302 1599±317 1621±295 0.970 1600±289 1746±385 1560±263 1808±403 0.132
Modified Gensini score 3.0±3.9 38.7±51.5* 14.8±10.2 60.4±63.6*
† <0.001 6.1±6.8 53.6±57.5
‡ 11.4±6.9 65.0±59.8
†‡ 0.004
Data are expressed as n (%) or mean±SD. Differences between groups were tested by chi-square and ANOVA with Bonferroni’s post hoc test performed if 
p<0.05. *p<0.01 vs. 0-vessel disease, 
†p<0.05 vs. 1-vessel disease, 
‡p<0.05 vs. 0-vessel disease. CAD: coronary artery disease, SBP: systolic blood pressure, DBP: 
diastolic blood pressure, DM: diabetes mellitus, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, FBS: fasting blood 
sugar, HbA1c: hemoglobin A1c, AGEs: advanced glycation end-products, baPWV: brachial-ankle pulse wave velocity, ANOVA: analysis of variance
Fig. 1. Comparison of serum levels of AGEs with and without obstructive CAD 
in diabetic patients. *p=0.010. AGEs: advanced glycation end-products, CAD: 
coronary artery disease.
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Serum advanced glycation end-products and brachial-ankle 
pulse wave velocity
Serum levels of AGEs were not significantly correlated with baP-
WV in diabetics (r=0.178, p=0.247) or non-diabetics (r=-0.113, p= 
0.259). BaPWV was also not significantly different in diabetics (1746± 
385 vs. 160±289 cm/s, respectively; p=0.320) or non-diabetics (1612± 
302 vs. 1622±464 cm/s, respectively; p=0.893), with or without 
obstructive CAD.
Serum advanced glycation end-products and other laboratory 
data
Serum levels of AGEs were not significantly correlated with hemo-
globin A1c (HbA1c) (r=-0.147, p=0.347) and serum creatinine (r=0.256, 
p=0.093) in diabetics.
Discussion
Diabetes is closely associated with macrovascular and microvas-
cular disease. As a potential pathophysiologic mechanism for vas-
cular complications related to diabetes, recent studies have focused 
on the role of AGEs, a biochemically diverse group of compounds 
that accumulate with aging, and according to the status of renal im-
pairment and diabetic state.
Advanced glycation end-products-mediated intramolecular and 
intermolecular cross-linking of collagen in the arterial wall lead to 
a decrease in enzymatic proteolysis and degradation rate by altering 
its surface charge and packing density, ultimately reducing arterial 
compliance.
15)16) Increased arterial stiffness and decreased vascular 
distensibility leads to increased systolic pressure and cardiac after-
load, and decreased diastolic blood pressure that could potentially 
compromise coronary blood flow.
7)8) Increased arterial stiffness is 
reflected in increased PWV, and is known to be a predictor of coro-
nary heart disease, stroke, and cardiovascular mortality.
17)18)
There are many recognized binding proteins for AGEs, some of 
which act as receptors, such as AGE receptors 1, 2, and 3, macro-
phage scavenger receptors 1 and 2, CD 34, megalin, ezrin, radixine, 
moesin protein, and RAGE. AGEs contribute to the impairment of 
endothelial function by reducing nitric oxide,
19) increasing the oxid-
ation of low density lipoprotein,
20) chemotaxis and activation of mo-
nocytes,
21) increasing generation of reactive oxygen species,
22) up-
regulating inflammation,
23) and, finally, lead to the development of 
atherosclerosis via these receptors.
24) Recently, the RAGE receptor 
has been recognized as being most biologically significant in the 
setting of atherosclerosis.
Previous studies reported serum levels of AGEs to be related to 
the degree of coronary atherosclerosis in both diabetics
9)10) and non-
Fig. 2. Receiver operating characteristics curve of serum levels of AGEs for 
obstructive CAD in diabetic patients. AUC=0.747; 95% CI 0.576 to 0.917; 
p=0.031. The cut-off point for levels of AGEs using the Youdean index was 
1.98 mU/mL (sensitivity=0.639, specificity=0.625).  AGEs: advanced glycation 
end-products, CAD: coronary artery disease. AUC: area under the curve, CI: 
confidence interval.  
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Fig. 3. Correlation between serum levels of AGEs and the number of diseased 
vessels with obstructive coronary artery disease in diabetes patients. r=0.504; 
p<0.001. AGEs: advanced glycation end-products.
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Table 2. Multiple regression analysis for the presence of obstructive CAD 
and the number of VDs in diabetics
Presence of obstructive  
CAD
Number of VDs
ß SE p ß SE p
Age - - - 0.022 0.011 0.053
Serum creatinine 0.625 0.268 0.025 0.847 0.506 0.102
AGEs 0.374 0.175 0.038 0.975 0.332 0.005
ß: standard regression cofficient, CAD: coronary artery disease, VDs: vessel 
diseases, AGEs: advanced glycation end-products, SE: standard error339 Ki-Bum Won, et al.
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diabetics
11) with CAD. Recently, Semba et al.
12) reported that incre-
ased serum levels of AGEs were associated with increased arterial 
stiffness among relatively healthy community-dwelling adults. This 
study evaluated the usefulness of serum levels of AGEs in predicting 
obstructive CAD, and the association between serum levels of AGEs 
and arterial stiffness using baPWV, the most widely-used PWV in-
dex, in both diabetic and non-diabetic patients suspected of having 
CAD. We postulated that serum levels of AGEs are useful in predict-
ing the presence of CAD, and that is associated with increased ar-
terial stiffness in patients suspected of having CAD. Our major find-
ing was that serum levels of AGEs were significantly higher in dia-
betic patients with obstructive CAD than in those without obstruc-
tive CAD, and reflected the severity of coronary atherosclerosis irres-
pective of arterial stiffness as measured by baPWV in diabetic pa-
tients. Although a trend of increasing arterial stiffness in diabetic 
patients with obstructive CAD was noted, baPWV was not correlated 
with serum levels of AGEs or showed significant difference between 
the absence and presence of CAD in diabetes. This may suggest that 
the receptor dependent actions of AGEs, through receptors such as 
RAGE, tend to be more potent than increased arterial stiffness in 
the genesis of coronary atherosclerotic disease, and also suggests 
that an increase in serum AGEs more precisely reflects the progres-
sion of atherosis than increased arterial wall stiffness in patients 
with diabetes. Some of the increase in serum AGEs may also repre-
sent increased modification of low density lipoprotein as a result 
of glycation, which plays a central role in the development of ath-
erosclerosis.
25) Although a PWV is good method to predict cardio-
vascular events, evaluation of PWV and serum levels of AGEs to-
gether may be more effective to predict CAD in diabetic patients, 
especially within normal range of PWV value. Additionally, it is im-
portant to note that serum levels of AGEs are not increased with 
obstructive CAD or reflect the severity of coronary atherosclerosis 
in non-diabetic patients. This result may support the critical role for 
AGEs in the pathogenesis of coronary atherosclerosis in diabetic 
individuals.
Unlike Semba et al.
12) who reported that increased serum levels 
of AGEs were associated with increased arterial stiffness, our find-
ing did not showed significant association between serum AGEs 
and baPWV in both diabetics and non-diabetics. This might be 
caused by the difference in study population. The aforementioned 
study examined relatively healthy community-dwelling adults. By 
comparison, our study population was high-risk patients who had 
been referred to a tertiary referral hospital to be evaluated for sus-
pected CAD. It might be also interpreted that increased serum lev-
els of AGEs might more accurately reflect the progression of coro-
nary atherosis than increased arterial stiffness in diabetic patients 
with suspected of having CAD.
Previous studies have suggested that chronic hyperglycemia con-
tributes to increased cardiovascular risk, and one potential mecha-
nism may be through the formation of AGEs.
3-5) However, Ono et 
al.
26) found that serum levels of AGEs did not correlate with serum 
HbA1C in patients whose serum levels of creatinine were <4.0 mg/
dL. Kilhovd et al.
9) also reported a lack of significant correlation be-
tween serum AGEs and HbA1c. Kiuchi et al.
10) found that serum lev-
els of AGEs were not correlated with recent serum HbA1C, but were 
positively correlated with serum mean 4-year HbA1C. We also found 
a lack of significant correlation between serum levels of AGEs and 
serum HbA1C in diabetics. This was probably caused by a different 
turnover and a time lag between the production of AGEs and re-
moval from tissue AGEs accumulation, and may suggest that long 
term poor glycemic control is associated with AGEs production.
Renal function affects serum levels of AGEs. Makita et al.
27) re-
ported that serum levels of AGEs were increased in end stage renal 
disease but not in normal renal function. In our study, only two pa-
tients had decreased renal function (serum levels of creatinine >1.5 
mg/dL), and there were no end stage renal disease patients. Multi-
ple regression analysis demonstrated that serum creatinine is relat-
ed to the presence of obstructive CAD, but not independently asso-
ciated with the number of VDs.
There were some limitations to this study. The accurate indicator 
reflecting central arterial stiffness has been considered to be aortic 
PWV measured as the carotid-femoral PWV (cfPWV). In this study, 
however, we used the baPWV, which has been increasingly used as 
an index of arterial stiffness, because the automatic waveform an-
alyzer did not provide the value of cfPWV. A baPWV is indirectly es-
timated using PWV from the heart to the brachial and posterior tibi-
al arteries, because the pulse wave does not propagate directly 
from the brachial arteries to the posterior tibial arteries in the same 
arterial tree. Also, the peripheral arteries do not represent aging and 
disease-related changes as do the central arteries. Despite these 
limitations of baPWV, previous studies have suggested that baPWV 
is a useful measure for arterial stiffness. Yamashina et al.
28) reported 
that baPWV could able to be considered an acceptable marker with 
an efficacy comparable to that of cfPWV. Sugawara et al.
29) also re-
ported that baPWV provide similar qualitative information, which 
was derived from central arterial stiffness. Thus, it may be reason-
able to use baPWV for evaluation of central arterial stiffness in this 
study. Another limitation of this study is that we did not evaluate 
other structurally-identified AGEs such as pentosidine, which could 
be associated with CAD, and the RAGE receptor, which is known to 
contribute significantly to the development of atherosclerosis in 
both diabetic and non-diabetic subjects. 
In summary, the serum level of AGE is an independent predictor 
of obstructive CAD, and reflect the severity of coronary atheroscle-340  Advanced Glycation End-Products and Coronary Artery Disease
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rosis irrespective of arterial stiffness only in diabetic patients with 
suspected CAD. Evaluation of PWV and serum AGEs together may 
be more effective to identify the risk of CAD in diabetic patients.
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